We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biochemical Hypoglycemia Associated with Risk of Hypoglycemia

By LabMedica International staff writers
Posted on 24 Jan 2019
Print article
Image: Testing blood glucose regularly allows for glycemic control strategy (Photo courtesy of the American Academy of Family Physicians).
Image: Testing blood glucose regularly allows for glycemic control strategy (Photo courtesy of the American Academy of Family Physicians).
To optimize diabetes management, it is essential to have assessments of both hyperglycemia and hypoglycemia. Glycated hemoglobin (HbA1c) is primarily a measure of hyperglycemia, but it provides no indication of the frequency or severity of hypoglycemia.

However, combining HbA1c with continuous glucose monitoring (CGM) provides not only measures of hypoglycemia and hyperglycemia but also information about the patterns of glycemia over the course of the day. Severe hypoglycemia (SH) may result in a variety of symptoms including clumsiness, trouble talking, confusion, loss of consciousness, seizures or death. A feeling of hunger, sweating, shakiness and weakness may also be present.

Scientists at the Jaeb Center for Health Research (Tampa, FL, USA) and their colleagues, analyzed data collected from Diabetes Control and Complications Trial. Glycemic data used in the analyses included the quarterly 7-point glucose measurements and recorded SH events. The 7-point testing consisted of blood samples collected in capillary tubes pre- and 90 min post meals and at bedtime that were sent to the central laboratory. For each 7-point testing day, the frequency of values <70 and <54 mg/dL was computed.

The team found that the risk of SH during a 3-month period was substantially higher when there was at least one hypoglycemic blood glucose value in the preceding 7-point profile, with similar results seen for both the 70 mg/dL (rate ratio = 3.0) and 54 mg/dL (rate ratio = 2.7) thresholds. The risk of an SH event during the 3-month period was more than twofold greater when there was at least one hypoglycemic blood glucose measurement on the 7-point testing, and risk increased further when there was more than one hypoglycemic blood glucose concentration.

The authors concluded that the occurrence of biochemical hypoglycemia <70 or <54 mg/dL is associated with an increased risk of SH. For this reason as well as the deleterious effects of hypoglycemia on glucose counter-regulation and hypoglycemia awareness, cognition, quality of life, and arrhythmias, it is important in diabetes management to avoid hypoglycemic glucose levels as much as possible. Satish Garg, MD, a Professor of Medicine and Pediatrics, said, “Severe hypoglycemia is a significant hurdle for intensifying insulin therapy in patients with T1D. Beck and colleagues emphasize the increased risk of future severe hypoglycemia in patients with any level of biochemical hypoglycemia.” The study was published on January 8, 2019, in the journal Diabetes Technology & Therapeutics.

Related Links:
Jaeb Center for Health Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: ColoSense is the first FDA-approved RNA-based molecular screening test for qualitative detection of colorectal cancer (Photo courtesy of Geneoscopy)

RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer

Colorectal cancer (CRC) ranks as the second most lethal cancer in the United States. Nevertheless, many Americans eligible for screening do not undergo testing due to limited access or reluctance towards... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more